Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

Related Articles by Review for PubMed (Select 23560600)

1.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):179-93. doi: 10.1089/cap.2012.0093. Epub 2013 Apr 6. Review.

2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
4.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Review.

PMID:
24982313
6.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
7.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
8.
9.

Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.

Fredriksen M, Halmøy A, Faraone SV, Haavik J.

Eur Neuropsychopharmacol. 2013 Jun;23(6):508-27. doi: 10.1016/j.euroneuro.2012.07.016. Epub 2012 Aug 20. Review.

PMID:
22917983
10.

Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.

Slatkoff J, Greenfield B.

Expert Opin Investig Drugs. 2006 Jun;15(6):649-67. Review.

PMID:
16732717
11.

Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.

Bushe CJ, Savill NC.

J Psychopharmacol. 2014 Mar;28(3):204-11. doi: 10.1177/0269881113478475. Epub 2013 Feb 25. Review.

PMID:
23438503
12.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
13.

Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.

Ramos-Quiroga JA, Montoya A, Kutzelnigg A, Deberdt W, Sobanski E.

Curr Med Res Opin. 2013 Sep;29(9):1093-104. doi: 10.1185/03007995.2013.812961. Epub 2013 Jul 2. Review. Erratum in: Curr Med Res Opin. 2013 Nov;29(11):1573.

PMID:
23742051
14.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
15.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
16.

Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.

Corman SL, Fedutes BA, Culley CM.

Am J Health Syst Pharm. 2004 Nov 15;61(22):2391-9. Review.

PMID:
15581262
17.

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.

Pringsheim T, Steeves T.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD007990. doi: 10.1002/14651858.CD007990.pub2. Review.

PMID:
21491404
18.

[Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].

Wiesegger G, Kienbacher C, Pellegrini E, Scheidinger H, Vesely C, Bangerl W, Friedrich M.

Neuropsychiatr. 2007;21(3):187-206. Review. German.

PMID:
17915180
19.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

20.

[My child is so restless].

Schlamp D.

MMW Fortschr Med. 2007 Mar 8;149(10):39-40. Review. German.

PMID:
17408047
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk